Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-14 8:45 pm Unchanged |
2024-08-12 | 13D | Savara Inc. SVRA |
Growth Equity Opportunities 17 LLC | 24,471,264 14.900% |
0 (Unchanged) |
Filing History |
| 2023-07-26 4:57 pm Purchase |
2023-07-17 | 13D | Savara Inc. SVRA |
Growth Equity Opportunities 17 LLC | 24,471,264 18.100% |
333,333 (+1.38%) |
Filing History |
| 2023-05-02 5:26 pm Sale |
2023-04-18 | 13D | Satsuma Pharmaceuticals, Inc. STSA |
Growth Equity Opportunities 17 LLC | 0 0.000% |
-2,488,587 (Position Closed) |
Filing History |
| 2023-02-03 5:27 pm Sale |
2023-01-27 | 13D | Geron Corporation GERN |
Growth Equity Opportunities 17 LLC | 0 0.000% |
-20,192,307 (Position Closed) |
Filing History |
| 2023-01-27 4:58 pm Sale |
2023-01-20 | 13D | Satsuma Pharmaceuticals, Inc. STSA |
Growth Equity Opportunities 17 LLC | 2,488,587 7.500% |
-504,371 (-16.85%) |
Filing History |
| 2022-08-12 5:15 pm Sale |
2022-07-22 | 13D | VistaGen Therapeutics, Inc. VTGN |
Growth Equity Opportunities 17 LLC | 0 0.000% |
-543,420 (Position Closed) |
Filing History |
| 2021-04-29 10:17 am Purchase |
2021-03-26 | 13D | VistaGen Therapeutics, Inc. VTGN |
Growth Equity Opportunities 17 LLC | 543,420 8.600% |
231,420 (+74.17%) |
Filing History |
| 2021-03-25 5:10 pm Purchase |
2021-03-15 | 13D | Savara Inc. SVRA |
Growth Equity Opportunities 17 LLC | 24,137,931 24.200% |
24,137,931 (New Position) |
Filing History |
| 2021-03-15 2:52 pm Purchase |
2021-03-03 | 13D | Satsuma Pharmaceuticals, Inc. STSA |
Growth Equity Opportunities 17 LLC | 2,992,958 9.500% |
2,992,958 (New Position) |
Filing History |
| 2021-01-04 06:00 am Purchase |
2020-12-22 | 13D | VistaGen Therapeutics, Inc. VTGN |
Growth Equity Opportunities 17 LLC | 312,000 6.800% |
312,000 (New Position) |
Filing History |
| 2020-06-04 2:58 pm Purchase |
2020-05-27 | 13D | Geron Corporation GERN |
Growth Equity Opportunities 17 LLC | 20,192,307 9.600% |
20,192,307 (New Position) |
Filing History |